# Home Reported Outcomes in C3G Study

> **NCT07029542** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 100 (estimated)

## Conditions studied

- C3 Glomerulopathy

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07029542
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-07
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07029542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07029542, "Home Reported Outcomes in C3G Study". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT07029542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*